ABUS
Price
$4.41
Change
-$0.02 (-0.45%)
Updated
Dec 4, 04:59 PM (EDT)
Capitalization
852M
84 days until earnings call
Intraday BUY SELL Signals
BMRN
Price
$53.85
Change
-$0.46 (-0.85%)
Updated
Dec 4, 04:59 PM (EDT)
Capitalization
10.43B
83 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ABUS vs BMRN

Header iconABUS vs BMRN Comparison
Open Charts ABUS vs BMRNBanner chart's image
Arbutus Biopharma
Price$4.41
Change-$0.02 (-0.45%)
Volume$40.49K
Capitalization852M
BioMarin Pharmaceutical
Price$53.85
Change-$0.46 (-0.85%)
Volume$48.91K
Capitalization10.43B
ABUS vs BMRN Comparison Chart in %
ABUS
Daily Signal:
Gain/Loss:
BMRN
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ABUS vs. BMRN commentary
Dec 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABUS is a Hold and BMRN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 05, 2025
Stock price -- (ABUS: $4.43 vs. BMRN: $54.31)
Brand notoriety: ABUS and BMRN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABUS: 196% vs. BMRN: 79%
Market capitalization -- ABUS: $852M vs. BMRN: $10.43B
ABUS [@Biotechnology] is valued at $852M. BMRN’s [@Biotechnology] market capitalization is $10.43B. The market cap for tickers in the [@Biotechnology] industry ranges from $117.5B to $0. The average market capitalization across the [@Biotechnology] industry is $2.2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABUS’s FA Score shows that 0 FA rating(s) are green whileBMRN’s FA Score has 0 green FA rating(s).

  • ABUS’s FA Score: 0 green, 5 red.
  • BMRN’s FA Score: 0 green, 5 red.
According to our system of comparison, both ABUS and BMRN are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABUS’s TA Score shows that 3 TA indicator(s) are bullish while BMRN’s TA Score has 5 bullish TA indicator(s).

  • ABUS’s TA Score: 3 bullish, 6 bearish.
  • BMRN’s TA Score: 5 bullish, 2 bearish.
According to our system of comparison, BMRN is a better buy in the short-term than ABUS.

Price Growth

ABUS (@Biotechnology) experienced а +0.45% price change this week, while BMRN (@Biotechnology) price change was -2.18% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.21%. For the same industry, the average monthly price growth was +5.86%, and the average quarterly price growth was +56.03%.

Reported Earning Dates

ABUS is expected to report earnings on Feb 26, 2026.

BMRN is expected to report earnings on Feb 25, 2026.

Industries' Descriptions

@Biotechnology (+1.21% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BMRN($10.4B) has a higher market cap than ABUS($852M). ABUS YTD gains are higher at: 35.474 vs. BMRN (-17.374). BMRN has higher annual earnings (EBITDA): 934M vs. ABUS (-53.13M). BMRN has more cash in the bank: 1.43B vs. ABUS (98.1M). ABUS has less debt than BMRN: ABUS (1.09M) vs BMRN (604M). BMRN has higher revenues than ABUS: BMRN (3.06B) vs ABUS (15.4M).
ABUSBMRNABUS / BMRN
Capitalization852M10.4B8%
EBITDA-53.13M934M-6%
Gain YTD35.474-17.374-204%
P/E RatioN/A20.19-
Revenue15.4M3.06B1%
Total Cash98.1M1.43B7%
Total Debt1.09M604M0%
FUNDAMENTALS RATINGS
ABUS vs BMRN: Fundamental Ratings
ABUS
BMRN
OUTLOOK RATING
1..100
6571
VALUATION
overvalued / fair valued / undervalued
1..100
56
Fair valued
68
Overvalued
PROFIT vs RISK RATING
1..100
68100
SMR RATING
1..100
9764
PRICE GROWTH RATING
1..100
5160
P/E GROWTH RATING
1..100
10093
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ABUS's Valuation (56) in the Biotechnology industry is in the same range as BMRN (68). This means that ABUS’s stock grew similarly to BMRN’s over the last 12 months.

ABUS's Profit vs Risk Rating (68) in the Biotechnology industry is in the same range as BMRN (100). This means that ABUS’s stock grew similarly to BMRN’s over the last 12 months.

BMRN's SMR Rating (64) in the Biotechnology industry is somewhat better than the same rating for ABUS (97). This means that BMRN’s stock grew somewhat faster than ABUS’s over the last 12 months.

ABUS's Price Growth Rating (51) in the Biotechnology industry is in the same range as BMRN (60). This means that ABUS’s stock grew similarly to BMRN’s over the last 12 months.

BMRN's P/E Growth Rating (93) in the Biotechnology industry is in the same range as ABUS (100). This means that BMRN’s stock grew similarly to ABUS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABUSBMRN
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
75%
Momentum
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
62%
MACD
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 2 days ago
60%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
65%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
76%
Bullish Trend 2 days ago
53%
Advances
ODDS (%)
Bullish Trend 9 days ago
78%
Bullish Trend 10 days ago
58%
Declines
ODDS (%)
Bearish Trend 15 days ago
77%
Bearish Trend 15 days ago
62%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
86%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
86%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
ABUS
Daily Signal:
Gain/Loss:
BMRN
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JMCVX16.570.15
+0.91%
Janus Henderson Mid Cap Value T
RYHCX98.410.72
+0.74%
Rydex Health Care C
MKVFX17.730.07
+0.40%
MFS International Large Cap Value R3
ECEMX17.410.03
+0.17%
Parametric Emerging Markets C
PURYX63.31-0.01
-0.02%
Putnam U.S. Research Y

ABUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABUS has been loosely correlated with IDYA. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ABUS jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABUS
1D Price
Change %
ABUS100%
+6.24%
IDYA - ABUS
48%
Loosely correlated
+1.93%
ROIV - ABUS
46%
Loosely correlated
+2.99%
IMVT - ABUS
43%
Loosely correlated
+3.13%
ARRY - ABUS
43%
Loosely correlated
+4.28%
BMRN - ABUS
43%
Loosely correlated
+0.78%
More

BMRN and

Correlation & Price change

A.I.dvisor indicates that over the last year, BMRN has been loosely correlated with TECH. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if BMRN jumps, then TECH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BMRN
1D Price
Change %
BMRN100%
+0.78%
TECH - BMRN
55%
Loosely correlated
+1.38%
BEAM - BMRN
48%
Loosely correlated
+14.42%
SYRE - BMRN
47%
Loosely correlated
+13.38%
IRON - BMRN
46%
Loosely correlated
+2.96%
JAZZ - BMRN
45%
Loosely correlated
+0.23%
More